STOCK TITAN

Gain Therapeutics, Inc. - GANX STOCK NEWS

Welcome to our dedicated page for Gain Therapeutics news (Ticker: GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.

Gain Therapeutics, Inc. (NASDAQ: GANX) is a clinical-stage biotech company pioneering novel small molecule therapies for neurodegenerative diseases and rare genetic disorders through its proprietary computational drug discovery platform. This page serves as the definitive source for verified updates on clinical trials, research breakthroughs, and corporate developments.

Investors and researchers will find timely updates on the company’s lead candidate GT-02287 for Parkinson’s disease, along with pipeline progress across lysosomal storage disorders and oncology targets. Our curated news collection includes earnings reports, partnership announcements, and scientific presentations – all essential for understanding GANX’s position in the competitive biopharmaceutical landscape.

Key updates cover three critical areas: clinical trial milestones for brain-penetrant therapies, advancements in AI-driven target identification via the Magellan platform, and strategic collaborations accelerating therapeutic development. Bookmark this page to track how GANX’s focus on allosteric modulation could reshape treatment paradigms.

Rhea-AI Summary
Gain Therapeutics, Inc. (Nasdaq: GANX) Proposes Public Offering to Fund Neurodegenerative Disease Treatment Development. Gain Therapeutics, Inc. announced a proposed public offering of its common stock and warrants to fund the development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases, including GBA1 Parkinson’s disease. The offering is subject to market conditions, and the company expects to use the net proceeds for clinical and nonclinical development as well as general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.9%
Tags
-
Rhea-AI Summary
Gain Therapeutics, Inc. (Nasdaq: GANX) initiates Phase 1 clinical study of GT-02287, with dosing escalation on schedule. The company also presented compelling preclinical data at the International Congress of Parkinson’s Disease and Movement Disorders and announced financial results for the third quarter of 2023, highlighting recent corporate progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
-
Rhea-AI Summary
Gain Therapeutics announces dosing of first two subjects in Phase 1 clinical trial for GT-02287, its lead drug candidate for GBA1 Parkinson's disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.62%
Tags
Rhea-AI Summary
Gain Therapeutics CEO to participate in Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
conferences
-
Rhea-AI Summary
Gain Therapeutics CEO to present at Neurodegeneration Targets Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
conferences
-
Rhea-AI Summary
Gain Therapeutics receives approval to initiate Phase 1 clinical study for GT-02287 in GBA1-Parkinson's disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
Rhea-AI Summary
Gain Therapeutics announces preclinical data showing GT-02287 significantly decreases Parkinson's disease pathology and improves motor dysfunction
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
-
Rhea-AI Summary
Gain Therapeutics, Inc. (GANX) announces submission of HREC application for Phase 1 clinical study of GT-02287. Positive preclinical results and upcoming milestones highlighted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.33%
Tags
-
Rhea-AI Summary
Gain Therapeutics to participate in fireside chat at 2023 BTIG Virtual Biotechnology Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
conferences
Gain Therapeutics, Inc.

Nasdaq:GANX

GANX Rankings

GANX Stock Data

50.02M
26.49M
5.01%
7.64%
1.32%
Biotechnology
Pharmaceutical Preparations
Link
United States
BETHESDA